This is a routine board appointment with no immediate financial impact. Monitor for any strategic shifts in international commercial operations or audit committee oversight that may influence future filings.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $10.17entry
- T+1 · 14d ago +1.77%α +1.47% · $10.35
- T+5 · 8d ago +55.95%α +55.87% · $15.86
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xeris Biopharma appointed Menassie M. Taddese to its Board of Directors, effective November 2, 2026, increasing board size from 8 to 9 members. Taddese, a former President of Emerging Markets at Viatris and a 20+ year Pfizer veteran, brings global commercial leadership and financial expertise. He received an initial equity award with a combined grant date fair value of approximately $450,000 and will serve on the Audit Committee.
Key Facts
- Board expanded from 8 to 9 members; Menassie Taddese appointed as Class II director effective November 2, 2026
- Taddese will serve on the Audit Committee and is independent under Nasdaq standards
- Initial equity award of options and RSUs with combined grant date fair value of approximately $450,000
- Taddese previously served as President, Emerging Markets at Viatris and held senior roles at Pfizer for over 20 years
- No material transactions or arrangements between Taddese and the company requiring disclosure
Financial Impact
Initial director equity award of approximately $450,000 in options and RSUs; annual equity grants of approximately $300,000 starting after the 2027 annual meeting
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001867096-26-000095 |
| Exhibit: exh991boardappointmentpres.htm | 0001867096-26-000095 |
| Document: 0001867096-26-000095-index-headers.html | 0001867096-26-000095 |
| Document: 0001867096-26-000095-index.html | 0001867096-26-000095 |
| Document: 0001867096-26-000095.txt | 0001867096-26-000095 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Viewing Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers